N-acetyl-aspartate level is decreased in the prefrontal cortex in subjects at-risk for schizophrenia

Frontiers in Psychiatry

Volumn 4, Issue SEP, 2013, Pages

  Mondino, Marine ^a   Brunelin, Jerome ^a   Saoud, Mohamed ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

MRS; NAA; Prefrontal cortex; Risk; Schizophrenia; Vulnerability

Indexed keywords

CREATININE; N ACETYLASPARTIC ACID;

AGING; AMINO ACID BRAIN LEVEL; ARTICLE; HIGH RISK PATIENT; HUMAN; NEUROMODULATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PROTEIN DEFECT; RISK ASSESSMENT; SCHIZOPHRENIA; SECONDARY ANALYSIS; SYSTEMATIC REVIEW; VULNERABLE POPULATION;

EID: 84885368950     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2013.00099     Document Type: Article

References (41)

1. Sun D, Phillips L, Velakoulis D, Yung A, McGorry PD, Wood SJ, et al. Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals. Schizophr Res (2009) 108(1-3):85-92. doi:10.1016/j.schres.2008.11.026.
2. Harrison BJ, Yücel M, Shaw M, Brewer WJ, Nathan PJ, Strother SC, et al. Dysfunction of dorsolateral prefrontal cortex in antipsychotic-naïve schizophreniform psychosis. Psychiatry Res (2006) 148(1):23-31. doi:10.1016/j.pscychresns.2006.02.006.
3. Snitz BE, MacDonald A, Cohen JD, Cho RY, Becker T, Carter CS. Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment. Am J Psychiatry (2005) 162(12):2322-9. doi:10.1176/appi.ajp.162.12.2322.
4. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci (1993) 13(3):981-9.
5. Steen RG, Hamer RM, Lieberman JA. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology (2005) 30:1949-62. doi:10.1038/sj.npp.1300850.
6. Deicken RF, Johnson C, Pegues M. Proton magnetic resonance spectroscopy of the human brain in schizophrenia. Rev Neurosci (2000) 11(2-3):147-58.
7. Théberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RW, Rajakumar N, et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry (2003) 160(12):2231-3. doi:10.1176/appi.ajp.160.12.2231.
8. Ohrmann P, Siegmund A, Suslow T, Spitzberg K, Kersting A, Arolt V, et al. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res (2005) 73(2-3):153-7. doi:10.1016/j.schres.2004.08.021.
9. Wood SJ, Berger GE, Lambert M, Conus P, Velakoulis D, Stuart GW, et al. Prediction of functional outcome 18 months after a first psychotic episode: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry (2006) 63(9):969-76. doi:10.1001/archpsyc.63.9.969.
10. Bertolino A, Callicott JH, Mattay VS, Weidenhammer KM, Rakow R, Egan MF, et al. The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol Psychiatry (2001) 49:39-46. doi:10.1016/S0006-3223(00)00997-5.
11. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry (1987) 44(7):660-9. doi:10.1001/archpsyc.1987.01800190080012.
12. Nuechterlein KH, Dawson ME, Green MF. Information-processing abnormalities as neuropsychological vulnerability indicators for schizophrenia. Acta Psychiatr Scand (1994) 90(384):71-9. doi:10.1111/j.1600-0447.1994.tb05894.x.
13. Saoud M, d'Amato T, Gutknecht C, Triboulet P, Bertaud JP, Marie-Cardine M, et al. Neuropsychological deficit in siblings discordant for schizophrenia. Schizophr Bull (2000) 26(4):893-902. doi:10.1093/oxfordjournals.schbul.a033503.
14. Sham PC, MacLean CJ, Kendler KS. A typological model of schizophrenia based on age at onset, sex and familial morbidity. Acta Psychiatr Scand (1994) 89(2):135-41. doi:10.1111/j.1600-0447.1994.tb01501.x.
15. Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rössler A, Schultze-Lutter F, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry (2013) 70(1):107-20. doi:10.1001/jamapsychiatry.2013.269.
16. Brunelin J, d'Amato T, Brun P, Bediou B, Kallel L, Senn M, et al. Impaired verbal source monitoring in schizophrenia: an intermediate trait vulnerability marker? Schizophr Res (2007) 89:287-92. doi:10.1016/j.schres.2006.08.028.
17. Pantelis C, Yücel M, Bora E, Fornito A, Testa R, Brewer WJ, et al. Neurobiological markers of illness onset in psychosis and schizophrenia: the search for a moving target. Neuropsychol Rev (2009) 19:385-98. doi:10.1007/s11065-009-9114-1.
18. Allen P, Luigjes J, Howes OD, Egerton A, Hirao K, Valli I, et al. Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals. Schizophr Bull (2012) 38(6):1268-76. doi:10.1093/schbul/sbr194.
19. Jessen F, Scherk H, Träber F, Theyson S, Berning J, Tepest R, et al. Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia. Schizophr Res (2006) 87:81-8. doi:10.1016/j.schres.2006.06.011.
20. Hafner H, Maurer K, Ruhrmann S, Bechdolf A, Klosterkotter J, Wagner M, et al. Early detection and secondary prevention of psychosis: facts and visions. Eur Arch Psychiatry Clin Neurosci (2004) 254:117-28. doi:10.1007/s00406-004-0508-z.
21. Keshavan M, Montrose DM, Pierri JN, Dick EL, Rosenberg D, Talagala L, et al. Magnetic resonance imaging and spectroscopy in offspring at risk for schizophrenia: preliminary studies. Prog Neuropsychopharmacol Biol Psychiatry (1997) 21:1285-95. doi:10.1016/S0278-5846(97)00164-4.
22. Callicott JH, Egan MF, Bertolino A, Mattay VS, Langheim FJ, Frank JA, et al. Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: a possible intermediate neurobiological phenotype. Biol Psychiatry (1998) 44:941-50. doi:10.1016/S0006-3223(98)00264-9.
23. Brooks WM, Hodde-Vargas J, Vargas LA, Yeo RA, Ford CC, Hendren RL. Frontal lobe of children with schizophrenia disorders: a proton magnetic resonance spectroscopic study spectrum. Biol Psychiatry (1998) 43:263-9. doi:10.1016/S0006-3223(97)00462-9.
24. Block W, Bayer TA, Tepest R, Traber F, Rietschel M, Muller DJ, et al. Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study. Neurosci Lett (2000) 289:147-51. doi:10.1016/S0304-3940(00)01264-7.
25. Tibbo P, Hanstock C, Valiakalayil A, Allen P. 3-T Proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry (2004) 161:1116-8. doi:10.1176/appi.ajp.161.6.1116.
26. Purdon SE, Valiakalayil A, Hanstock CC, Seres P, Tibbo P. Elevated 3T proton MRS glutamate levels associated with poor continuous performance test (CPT-0X) scores and genetic risk for schizophrenia. Schizophr Res (2008) 99:218-24. doi:10.1016/j.schres.2007.11.028.
27. Yoo SY, Yeon S, Choi CH, Kang DH, Lee JM, Shin NY, et al. Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus. Schizophr Res (2009) 111:86-93. doi:10.1016/j.schres.2009.03.036.
28. LutkenhoffES, van Erp TG, Thomas MA, Therman S, Manninen M, Huttunen MO, et al. Proton MRS in twin pairs discordant for schizophrenia. Mol Psychiatry (2010) 15(3):308-18. doi:10.1038/mp.2008.87.
29. Hedges L, Olkin I. Statistical Methods for Meta-Analysis. New York: Academic Press (1985).
30. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York: Academic Press (1969).
31. Angelie E, Bonmartin A, Boudraa A, Gonnaud PM, Mallet JJ, Sappey-Marinier D. Regional differences and metabolic changes in normal aging of the human brain: proton MR spectroscopic imaging study. AJNR Am J Neuroradiol (2001) 22:119-27.
32. Brugger S, Davis JM, Leucht S, Stone JM. Proton magnetic resonance spectroscopy and illness stage in schizophrenia-a systematic review and meta-analysis. Biol Psychiatry (2011) 69(5):495-503. doi:10.1016/j.biopsych.2010.10.004.
33. Wood SJ, Berger G, Velakoulis D, Phillips LJ, McGorry PD, Yung AR, et al. Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals. Schizophr Bull (2003) 29:831-43. doi:10.1093/oxfordjournals.schbul.a007049.
34. Wobrock T, Kamer T, Roy A, Vogeley K, Schneider-Axmann T, Wagner M, et al. Reduction of the internal capsule in families affected with schizophrenia. Biol Psychiatry (2008) 63:65-71. doi:10.1016/j.biopsych.2007.02.026.
35. Kim JH, Chang KH, Na DG, Song IC, Kim SJ, Kwon BJ, et al. Comparison of 1.5T and 3T 1H MR spectroscopy for human brain tumors. Korean J Radiol (2006) 7(3):156-61. doi:10.3348/kjr.2006.7.3.156.
36. Jissendi Tchofo P, Balériaux D. Brain (1)H-MR spectroscopy in clinical neuroimaging at 3T. J Neuroradiol (2009) 36(1):24-40. doi:10.1016/j.neurad.2008.04.001.
37. Szulc A, Galinska-Skok B, Waszkiewicz N, Bibulowicz D, Konarzewska B, Tarasow E. Proton magnetic resonance spectroscopy changes after antipsychotic treatment. Curr Med Chem (2013) 20(3):414-27. doi:10.2174/092986713804870783.
38. Zabala A, Sánchez-González J, Parellada M, Moreno DM, Reig S, Burdalo MT, et al. Findings of proton magnetic resonance spectrometry in the dorsolateral prefrontal cortex in adolescents with first episodes of psychosis. Psychiatry Res (2007) 156(1):33-42. doi:10.1016/j.pscychresns.2006.12.016.
39. Molina V, Sánchez J, Reig S, Sanz J, Benito C, Santamarta C, et al. N-acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration. Schizophr Res (2005) 73(2-3):209-19. doi:10.1016/j.schres.2004.02.001.
40. Delamillieure P, Constans JM, Fernandez J, Brazo P, Benali K, Courthéoux P, et al. Proton magnetic resonance spectroscopy (1H MRS) in schizophrenia: investigation of the right and left hippocampus, thalamus, and prefrontal cortex. Schizophr Bull (2002) 28(2):329-39. doi:10.1093/oxfordjournals.schbul.a006942.
41. Pantelis C, Velakoulis D, Wood SJ, Yücel M, Yung AR, Phillips LJ, et al. Neuroimaging and emerging psychotic disorders: the Melbourne ultra-high risk studies. Int Rev Psychiatry (2007) 19(4):371-81. doi:10.1080/09540260701512079.